Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
- Conditions
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 125
- Registration Number
- NCT02648464
- Locations
- 🇫🇮
Päijät-Häme Central Hospital, Lahti, Finland
🇫🇮South Karelia Central Hospital, Lappeenranta, Finland
🇫🇮North Karelia Central Hospital, Joensuu, Finland
Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2019-10-01
- Target Recruit Count
- 186
- Registration Number
- NCT02644499
- Locations
- 🇮🇳
Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, Pondicherry UT, India
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Alison Sehgal, MD, MS
- Target Recruit Count
- 1
- Registration Number
- NCT02631252
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)
- Conditions
- Interventions
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Matthias Griese
- Target Recruit Count
- 80
- Registration Number
- NCT02615938
- Locations
- 🇩🇪
Justus-Liebig-Universität, Allgemeine Pädiatrie u. Neonatologie, Gießen, Hessen, Germany
🇩🇪Universitätsklinikum Frankfurt, Pneumologie, Allergologie, Mukoviszidose, Frankfurt, Hessen, Germany
🇩🇪Charité Berlin, Klinik für Pädiatrie, Berlin, Germany
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 144
- Registration Number
- NCT02603146
- Locations
- 🇺🇸
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology, Ann Arbor, Michigan, United States
🇺🇸University of Nebraska Medical Center: Division of Rheumatology, Omaha, Nebraska, United States
🇺🇸Cedars Sinai Medical Center: Division of Rheumatology, Los Angeles, California, United States
Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 30
- Registration Number
- NCT02595346
- Locations
- 🇫🇷
Rouen University Hospital, Rouen, France
Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- SEARCH Research Foundation
- Target Recruit Count
- 15
- Registration Number
- NCT02475915
- Locations
- 🇹🇭
SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
- Conditions
- Interventions
- Other: Lab WorkDrug: Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)Drug: Certolizumab pegol (CDP870, tradename Cimzia)Drug: HydroxychloroquineDrug: SulfasalazineDrug: MedrolDrug: PrednisoneDrug: TriamcinoloneDrug: NaproxenDrug: LeflunomideDrug: MethotrexateDrug: humira
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 32
- Registration Number
- NCT02451748
- Locations
- 🇺🇸
Outpatient Care Center, Chicago, Illinois, United States
Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE
- Conditions
- Interventions
- First Posted Date
- 2015-05-14
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 50
- Registration Number
- NCT02444728
- Locations
- 🇨🇳
Beijng Hospital, Beijing, China
🇨🇳the Affiliated Hospital to Bangbu Medical University, Bangbu, Anhui, China
🇨🇳Hebei Provincial Hospital, Shijiazhuang, Hebei, China
Very Early Versus Delayed Etanercept in Patients With RA
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 120
- Registration Number
- NCT02433184
- Locations
- 🇬🇧
Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.